Asahi Kasei Pharma To Expand Naftopidil Market Share
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Pharma will expand market share for benign prostate hyperplasia drug Flivas (naftopidil) in Japan. The company obtained the drug's intellectual property rights from Roche Diagnostics. Asahi Kasei sees a stronger demand for the drug since the sales of competeing drugAvishot (naftlopidil), manufactured by Organon Japan (now Schering Plough) will be halted by Schering Plough by March 2010. Asahi also plans to increase medical representatives by 50 percent to 900 by 2014 and double sales from ¥50 billion to ¥100 billions by 2015. To speed new drug development, the company aims to increase research and development investment by ¥2 billion each year for 2009 and 2010, and reach ¥14 billion in 2010. (Click here for more - Japanese language
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.